Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. [PDF]
, 2019 BACKGROUND: Ticagrelor is an oral P2Y12 inhibitor that is used with aspirin to reduce the risk of ischemic events among patients with acute coronary syndromes or previous myocardial infarction.
Arnold, Susan E. +8 more
core +1 more source
Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal
Therapeutics and Clinical Risk Management, 2018 Marco Proietti,1–3 Giuseppe Boriani4 1Department of Neuroscience, IRCCS – Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy; 2Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK ...
Proietti M, Boriani G
doaj
Stroke Reperfusion Therapy Following Dabigatran Reversal With Idarucizumab in a National Cohort [PDF]
, 2021 openalex +1 more source
Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects [PDF]
, 2016 Paul Reilly +4 more
openalex +1 more source
Idarucizumab Dosing in Kidney Failure [PDF]
American Journal of Kidney Diseases, 2018 Luke Yip, Jou-Fang Deng
openaire +3 more sources
Dabigatran Reversal with Idarucizumab
New England Journal of Medicine, 2017 Pollack, Charles V. +2 more
openaire +7 more sources
A dabigatran iv. antidótumának, az idarucizumabnak első hazai alkalmazásai sürgős műtétek esetén = The first uses of iv. idarucizumab for dabigatran reversal in cases of urgent surgeries in Hungary [PDF]
, 2017 Barabás, Éva +8 more
core +1 more source
Patterns and trends of idarucizumab use in an Italian region: a probabilistic record-linkage approach in a real-life setting [PDF]
, 2020 Niccolò Lombardi +9 more
openalex +1 more source
Anaphylaxis after Idarucizumab Infusion [PDF]
Journal of Clinical Neurology, 2017 Jun Young Chang +6 more
openaire +2 more sources
A dabigatran-antidótum, az intravénás idarucizumab első hazai alkalmazása [PDF]
, 2017 Lajos Driesz +7 more
openalex +1 more source